Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2008

View Archived Issues

Nuclear orphan receptor Nur77 can be targeted with cytosporone B

Amgen targets BKCa channel for migraine treatment

Wyeth creates novel series of selective norepinephrine reuptake inhibitors

Federal Trade Commission clears Frensenius' acquisition of APP Pharmaceuticals

Debiopharm and EPFL initiate research project Debio 0826 in cancer

Evotec achieves third milestone under drug discovery contract with Boehringer Ingelheim

Dr. Reddy's signs agreements with Antares and Cosmederm for dermatology products

Preclinical study with AZD-6140 shows antiplatelet effect in a canine model of coronary thrombosis

Acucela and Otsuka establish codevelopment agreement for rebamipide

SIGA awarded contract to develop new smallpox indications for ST-246

Human Genome Sciences and Hospira sign manufacturing process development deal

Epix to regain worldwide commercialization rights to Vasovist

Priority review for ATryn BLA

Emergent receives USD 24 million contract from the HSS to develop AVP-21D9

Camurus and Wyeth sign option and license agreement in hemophilia therapeutics

Novel treatments for respiratory disorders disclosed in recent Merck Frosst patent

BioCryst presents results from BCX-4208 phase IIa trial in psoriasis

BioMS Medical's dirucotide granted FDA fast track for multiple sclerosis

Idenix reports results from proof-of-concept study for IDX-899 in HIV

Recent patents describe new treatment options for immunological disorders

ProtAffin granted FDA orphan drug designation for PA-401 in transplantation

Novel antiinflammatory agents claimed in recent Boehringer Ingelheim patent

Toctino (alitretinoin) receives marketing authorization in the U.K.

Yaz, a new low-dose oral contraceptive, launched in Europe by Bayer Schering Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...